GlaxoSmithKline Pakistan (KAR:GLAXO) Construction In Progress : ₨2,532 Mil (As of Mar. 2025)

View and export this data going back to 1953. Start your Free Trial

What is GlaxoSmithKline Pakistan Construction In Progress?

GlaxoSmithKline Pakistan's quarterly construction in progress increased from Sep. 2024 (₨1,986 Mil) to Dec. 2024 (₨3,087 Mil) but then declined from Dec. 2024 (₨3,087 Mil) to Mar. 2025 (₨2,532 Mil).

GlaxoSmithKline Pakistan's annual construction in progress increased from Dec. 2022 (₨1,236 Mil) to Dec. 2023 (₨1,295 Mil) and increased from Dec. 2023 (₨1,295 Mil) to Dec. 2024 (₨3,087 Mil).

GlaxoSmithKline Pakistan Construction In Progress Historical Data

The historical data trend for GlaxoSmithKline Pakistan's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GlaxoSmithKline Pakistan Construction In Progress Chart

GlaxoSmithKline Pakistan Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Construction In Progress

Get a 7-Day Free Trial

1,028.83

1,178.02

1,235.59

1,294.57

3,086.67

GlaxoSmithKline Pakistan Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Construction In Progress	Get a 7-Day Free Trial															1,748.14	1,764.59	1,986.48	3,086.67	2,531.69

GlaxoSmithKline Pakistan Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.

GlaxoSmithKline Pakistan Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » GlaxoSmithKline Pakistan Ltd (KAR:GLAXO) » Definitions » Construction In Progress

Comparable Companies

Traded in Other Exchanges

N/A

Address

35, Dockyard Road, West Wharf, Karachi, PAK, 74000

Website

https://www.pk.gsk.com

GlaxoSmithKline Pakistan Ltd is engaged in the research, development, and manufacturing of pharmaceutical medicines, vaccines, and consumer healthcare products. It is involved in Anti-infective, Respiratory, Vaccines, Dermatological, Gastrointestinal, Analgesics, Urology, Central Nervous System, Allergy, Cardiovascular, and Vitamins therapy areas. The operating business divisions are Pharmaceuticals and Consumer Healthcare. The pharmaceutical brands of the company include Augmentin, Seretide, Amoxicillin, Velosef, Zantac, and Calpol, and prominent vaccines include Synflorix, Infanrix Hexa, Rotarix, Engerix-B, Havrix, and Cervarix. The company derives maximum revenue from the Pharmaceuticals segment.

GlaxoSmithKline Pakistan Headlines

No Headlines